Boston, MA 10/15/2014 (wallstreetpr) – Quotient Ltd (NASDAQ:QTNT) announced that it has expanded its reagent red cell product line up by adding four new products in the series.
New Products
As cited in the article, Quotient gained the approval for four new products in the reagent red cell series. Quotient Ltd (NASDAQ:QTNT) will launch the products in the market by Oct-end. The latest additions to the portfolio are:
- ALBAcyte® Expanded Rh Negative Antibody Screen
- ALBAcyte® Antibody Identification Panel (16-cell)
- ALBAcyte® Antibody Screen (2-cell)
- ALBAzyme® Papain Solution Kit
Quotient has included several novel products in the new offerings, which expand its portfolio of the reagent red cell series of products. In this context, its President, Jeremy Stackawitz, commented that with the latest launch, Quotient Ltd (NASDAQ:QTNT) can fully address the demands of the expanded majority of blood bank labs. He said that Quotient has become a one-stop-shop for supplying all reagent red cells.
About The Products
The ALBAcyte® Expanded Rh Negative Antibody Screen is Quotient’s special product that serves more than a typical antibody screen. It is particularly useful for pregnant women, who have Rh-negative blood and have previously been treated with the Rh Immunoglobulin. The Rh-negative cells present in the product are capable of successfully detecting unexpected antibodies that are needed by the traditional screens.
ALBAcyte® Antibody Identification Panel (16-cell) is a complete antibody identification module. It has six complementary cells that will help in providing extra protection in antibody identification work ups.
ALBAcyte® Antibody Screen (2-cell) is o meet the special demand of some customers who prefer such a screen. Additionally, it is also ideal for those who frequently evaluate small-volume, such as pediatric samples. The red cells present in the product offer maximized homozygousity, which helps in optimizing the antibodies detection procedure.
The ALBAzyme® Papain Solution Kit combines enzyme and papain control, and can be used in combination with Quotient Ltd (NASDAQ:QTNT)’s existing ALBAcyte® Antibody Identification Panel (10-cell). The combination will allow easy evaluation of patient and auto-controls samples.
